Business Wire

MANHATTAN-ASSOCIATES

19.6.2024 09:01:31 CEST | Business Wire | Press release

Share
Staff Retention, Issues Managing Different Channels and Legacy Tech put Warehouse Operations in the Spotlight

Manhattan Associates Inc. (NASDAQ: MANH) today announced the findings of its 2024 ‘State of Warehouse Operations’ research in association with Vanson Bourne, highlighting the current challenges and key opportunities ahead for the sector.

As the global economy continues to recalibrate after a series of macro-economic and geopolitical events shook it to its core, procurement and supply chain professionals continue to face unique challenges. From labour retention and engagement and environmental concerns to technological advancements, raw material shortages, and the challenge presented by elevated consumer expectations across a myriad of channels, the forces shaping supply chain commerce are strong and varied.

Vanson Bourne interviewed 2,000 supply chain professionals in Spring 2024 across Australia, Belgium, Brazil, France, Germany, Italy, the Netherlands, Norway, Mexico, Spain, Sweden, and the UK. Respondents included both senior management and operational staff, and came from the manufacturing and production, logistics, pharmaceuticals, retail, automotive and CPG sectors.

In terms of the overriding challenges, almost all respondents (97%) believe their warehouse operations IT infrastructure requires at least some modernisation. 84% reported facing difficulties with staff retention, while 73% said the volume of goods passing through warehouses had increased over the past 12 months, exacerbating the problems they were already facing.

However, organisations also remained hopeful about the future, with 75% and 72% expecting Generative AI and robotics (respectively) to play a positive role in improving job satisfaction and functions, through reducing manual operations/increasing automation, and by streamlining workflows and reducing paperwork. As organisations look at ways to simplify operations, meet increased demand and enhance staff experiences, continuous supply chain innovation will be required to tackle emerging risks, while taking full advantage of new opportunities simultaneously.

Below are three key takeaways from the report aimed at helping supply chain professionals to plan a path to future successes:

  1. Warehouse operations are becoming more challenging for organisations and ensuring staff feel listened to, engaged and valued is important. A sizeable number of respondents cited staff-related challenges including recruiting/training short-term workers (41%) and ensuring productivity (40%) have grown significantly over the last 12 months.
  2. 28% of organisations surveyed highlighted that outdated IT hardware and software was the most pressing challenge they are currently facing. That adds up to a significant amount of fiscal and technological drag for almost a one in three of the companies surveyed.
  3. 26% of respondents said they are struggling to manage orders from different channels while 23% said that they were finding it difficult to meet heightened customer expectations on turnaround times.

Henri Seroux, senior vice president, EMEA at Manhattan Associates commented: “Warehouses are at the heart of a unified supply chain and centre of the fulfilment universe. Tackling the challenges highlighted in the report are key to the long-term competitiveness and success of companies. The findings underline the importance of looking forward and continuing to incorporate new technologies like micro services and Generative AI, future-proofing supply chains and allowing them to become revenue and customer service drivers in their own right.

“Ultimately, a more unified supply chain strategy creates efficiency, and that in turn creates sustainability, both in terms of economics and environment. And that can only be a good thing for P&Ls as well as the planet,” Seroux finished.

About Manhattan Associates

Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers.

Manhattan Associates designs, builds, and delivers leading edge cloud and on-premises solutions so that across the store, through your network or from your fulfillment center, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com.

Receive up-to-date product, customer and partner news directly from Manhattan Associates on Twitter, LinkedIn and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240619661878/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye